Side-by-side · Research reference

AdamaxvsOxytocin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/47 cited

BFDA-ApprovedHUMAN-REVIEWED11/51 cited

Adamax

ACTH(4-10) Analogue · Russian Nootropic

1.4×BDNF protein ↑Dolotov 2006

3×BDNF mRNA (exon III)Dolotov 2006

1.6×trkB phosphorylationDolotov 2006

Intranasal · Research Use Only

Oxytocin

Neuropeptide Hormone · FDA-Approved

24–48 IUIntranasal dose (research)Prinsen 2026 Burmester 2025

~3–20 minPlasma half-life

9 AAPeptide length

Intranasal · IV (obstetric)

01Mechanism of Action

Parameter

Adamax

Oxytocin

Primary target

Melanocortin receptors (MC-Rs) in hippocampus and cortex

Oxytocin receptors (OXTR) — hypothalamus, amygdala, hippocampus, ventral tegmental area

Pathway

ACTH(4-10) fragment → MC-R binding → BDNF/trkB upregulation → neurotrophic signaling

OXTR activation → Gq/11-coupled signaling → modulation of GABAergic, dopaminergic, serotonergic pathways → enhanced synaptic plasticity, neurogenesis, emotional regulation

Downstream effect

Increased hippocampal BDNF expression, trkB tyrosine phosphorylation, enhanced conditioned avoidance learning, circadian rhythm normalizationDolotov 2006 Arushanian 2008

Social bonding enhancement, trust behavior, gaze modulation, reciprocal eye contact, anti-inflammatory and antioxidant neuroprotection, reduced amygdala threat responsePaul 2026 Prinsen 2026 Yuan 2026

Feedback intact?

Non-endocrine — devoid of adrenal axis effectsvan 1978

Yes — endogenous oxytocin-mediated feedback via central and peripheral OXTR pathways

Origin

ACTH(4-10) fragment with modified amino acid sequence at positions 8, 9, 10Teter 2001

Endogenous 9-amino-acid peptide synthesized in hypothalamic paraventricular and supraoptic nuclei, released from posterior pituitaryPaul 2026

Antibody development

—

02Dosage Protocols

Parameter

Adamax

Oxytocin

Animal dose (rat)

50 mcg/kg body weightDolotov 2006

Single intranasal application; produced maximal BDNF response.

—

Route

IntranasalDolotov 2006 Smolnik 2000

—

Frequency

Single-dose or chronic administration protocols

Chronic dosing normalized circadian rhythms; single-dose produced acute BDNF elevation.

—

Human dose (exploratory)

Not established — limited human data

ACTH(4-10) and analogs dosed 30–60 mcg intranasally in early human studies.

—

Evidence basis

Animal (rodent, rabbit) studies; minimal human RCT data

—

Timing

Variable — chronic administration for circadian effects

—

Intranasal (research — autism, social cognition)

—

24–48 IUPrinsen 2026 Burmester 2025

Single dose; chronic dosing protocols vary (4–12 weeks documented).

Frequency (research)

—

Once daily to twice daily

IV (obstetric — labor induction)

—

0.5–2 mU/min, titrated every 30–60 min

FDA-approved Pitocin protocol; maximum 20–40 mU/min per institutional guidelines.

Evidence basis (social cognition)

—

Phase 1–2 RCTs in ASD, schizophrenia, social anxiety

Evidence basis (obstetric)

—

FDA-approved · standard-of-care

Duration (research protocols)

—

4–12 weeks chronic administrationPrinsen 2026

Half-life

—

~3–20 min (plasma); CNS effects persist longer

Timing (intranasal)

—

Morning or pre-social interaction

Acute effects within 30–90 minutes.

04Side Effects & Safety

Parameter

Adamax

Oxytocin

Cardiovascular effects

ACTH(4-10) fragments may have pressor and cardioaccelerator actions at high dosesGruber 1984

Effects attenuated by α/β-receptor antagonists; observed at 30–1000 nmol/kg IV in rats.

—

Natriuretic effect

ACTH(4-10) exhibited natriuretic activity at lower doses (7 nmol/kg)Gruber 1984

—

Behavioral suppression

Suppression of aggression, reduced orientation-cognition reactions in rabbitsTeter 2001

May reflect anxiolytic or stress-dampening profile.

—

Long-term safety

Unknown — chronic human safety data lacking

—

Nasal irritation (intranasal)

—

Mild dryness, congestion

Headache

—

Occasional, transient

Uterine hyperstimulation (IV obstetric)

—

Tachysystole, fetal distress — requires continuous monitoring

Negative interpretation bias (adolescents)

—

Increased negative interpretations of ambiguous social scenarios in female adolescents (with and without eating disorders)Burmester 2025

Hyponatremia (IV)

—

Water intoxication risk with prolonged high-dose IV infusion

Hypersensitivity

—

Rare allergic reactions

Individual variability

—

Salivary oxytocin levels show high subgroup variability in ASD populations; no consistent group-level differences vs controls in some studiesYılmazer 2025

Absolute Contraindications

Adamax

·Pregnancy and lactation (precautionary; no data)
·Active cardiovascular instability (due to potential pressor effects)

Oxytocin

·Fetal distress or abnormal fetal heart rate patterns (obstetric)
·Cephalopelvic disproportion
·Hypersensitivity to oxytocin

Relative Contraindications

Adamax

·Hypertension (monitor BP if using higher doses)
·Renal impairment (natriuretic effects may alter electrolyte balance)

Oxytocin

·Severe cardiovascular disease (obstetric use)
·Hypertonic or hyperactive uterus
·Prior uterine surgery or cesarean section (relative — use cautiously)

05Administration Protocol

Parameter

Adamax

Oxytocin

1. Reconstitution (if lyophilised)

Add sterile water or bacteriostatic water to lyophilised vial per manufacturer guidance. Roll gently — do not shake. Ensure clarity before use.

Administer 24–48 IU (typically 3–6 puffs per nostril) using nasal spray device. Patient should be seated, head tilted slightly forward. Avoid sniffing deeply; allow passive absorption.

2. Route

Intranasal administration is the primary route in animal and exploratory human studies. Delivered via nasal spray or dropper to ensure mucosal absorption.Dolotov 2006 Smolnik 2000

Administer 30–90 minutes before anticipated social interaction or cognitive assessment. Acute effects peak within 30–60 minutes.

3. Timing

Variable. Single-dose protocols for acute cognitive tasks; chronic daily dosing for circadian rhythm normalization and sustained neuroprotection.

Dilute oxytocin 10 units in 1000 mL isotonic saline. Initiate at 0.5–2 mU/min via infusion pump. Titrate every 30–60 minutes based on contraction pattern and fetal heart rate. Continuous electronic fetal monitoring required.

4. Storage

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within manufacturer-specified timeframe.

Store at 2–8 °C (refrigerated). Do not freeze. Protect from light. Discard if solution is discolored or contains precipitate.

5. Chronic dosing (research)

—

Chronic administration protocols (4–12 weeks) documented in pediatric ASD populations. Daily or twice-daily intranasal administration. Safety profile in chronic use still under investigation.

06Stack Synergy

Adamax

+ Semax

Moderate

View Semax →

Both Adamax and Semax are ACTH(4-10)-derived nootropics acting via melanocortin receptors and BDNF upregulation. Adamax has distinct amino acid modifications at positions 8-10, potentially offering complementary receptor binding profiles or metabolic stability. Stacking may amplify neurotrophic signaling and cognitive enhancement, though direct synergy studies are absent. Theoretical multi-pathway benefit.

Adamax: Research dose intranasal
Semax: 300–600 mcg intranasal
Frequency: Once daily, morning or pre-cognitive task
Primary benefit: Enhanced BDNF upregulation, cognitive performance, neuroprotection

Oxytocin

— no documented stacks